ORMP Stock Overview

Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. More details

ORMP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap (₪96M)

Does not have meaningful revenue ($2M)

Volatile share price over the past 3 months compared to the IL market

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Oramed Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Oramed Pharmaceuticals
Historical stock prices
Current Share Price	US$7.65
52 Week High	US$10.00
52 Week Low	US$7.01
Beta	1.65
1 Month Change	-6.76%
3 Month Change	2.29%
1 Year Change	-6.15%
3 Year Change	-47.98%
5 Year Change	-38.69%
Change since IPO	-74.65%

Recent updates

Shareholder Returns

	ORMP	IL Pharmaceuticals	IL Market
7D	0.5%	-0.3%	2.7%
1Y	-6.1%	-43.0%	43.1%

Return vs Industry: ORMP exceeded the IL Pharmaceuticals industry which returned -40.5% over the past year.

Return vs Market: ORMP underperformed the IL Market which returned 42.6% over the past year.

Price Volatility

Is ORMP's price volatile compared to industry and market?
ORMP volatility
ORMP Average Weekly Movement	6.7%
Pharmaceuticals Industry Average Movement	6.2%
Market Average Movement	5.2%
10% most volatile stocks in IL Market	8.3%
10% least volatile stocks in IL Market	3.7%

Stable Share Price: ORMP's share price has been volatile over the past 3 months compared to the IL market.

Volatility Over Time: ORMP's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of IL stocks.

About the Company

Founded	Employees	CEO	Website
2002	n/a	Nadav Kidron	www.oramed.com

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.

Oramed Pharmaceuticals Inc. Fundamentals Summary

How do Oramed Pharmaceuticals's earnings and revenue compare to its market cap?
ORMP fundamental statistics
Market cap	₪335.88m
Earnings (TTM)	-₪99.22m
Revenue (TTM)	₪7.03m

47.8x

P/S Ratio

-3.4x

P/E Ratio

Is ORMP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ORMP income statement (TTM)
Revenue	US$2.00m
Cost of Revenue	US$1.99m
Gross Profit	US$13.00k
Other Expenses	US$28.25m
Earnings	-US$28.24m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.69
Gross Margin	0.65%
Net Profit Margin	-1,411.90%
Debt/Equity Ratio	0%

How did ORMP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/06/01 19:48
End of Day Share Price	2025/05/29 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oramed Pharmaceuticals Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Andrew D'Silva	B. Riley Securities, Inc.
Edward Nash	Canaccord Genuity
Christopher James	FBR Capital Markets & Co.

ORMP Stock Overview

Risk Analysis

Oramed Pharmaceuticals Inc. Competitors

InterCure

Rekah Pharmaceutical Industry

Seach Medical Group

Y.B Urban Renewal - Residential Development

Price History & Performance

Recent News & Updates

New major risk - Share price stability

New minor risk - Profitability

Investor sentiment improves as stock rises 25%

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

New major risk - Earnings quality

Recent updates

New major risk - Share price stability

New minor risk - Profitability

Investor sentiment improves as stock rises 25%

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

New major risk - Earnings quality

New minor risk - Market cap size

Investor sentiment improves as stock rises 19%

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024

Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)

New minor risk - Market cap size

Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings released: EPS: US$0.14 (vs US$0.94 loss in FY 2022)

New major risk - Share price stability

Insufficient new directors

Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024

Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.03 loss per share (vs US$0.27 loss in 2Q 2022)

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

First quarter 2023 earnings released: US$0.085 loss per share (vs US$0.27 loss in 1Q 2022)

Independent Director recently bought ₪70k worth of stock

Independent Director recently bought ₪513k worth of stock

Full year 2022 earnings released: US$0.94 loss per share (vs US$0.94 loss in FY 2021)

Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 2Q 2021)

High number of new and inexperienced directors

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 1Q 2021)

Full year 2021 earnings released: US$0.94 loss per share (vs US$0.90 loss in FY 2020)

Independent Chairman of the Board recently sold ₪303k worth of stock

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Independent Chairman of the Board recently sold ₪1.4m worth of stock

Independent Director Xiaoming Gao has left the company

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.098 loss in 3Q 2020)

CFO, Treasurer & Secretary Avraham Gabay has left the company

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2020)

New 90-day high: ₪36.50

New 90-day high: ₪21.96

Revenue beats expectations

First quarter 2021 earnings released: US$0.23 loss per share

New 90-day high: ₪16.00

Full year 2020 earnings released: US$0.56 loss per share

Revenue misses expectations

New 90-day low: ₪8.64

New 90-day low: ₪9.45

Shareholder Returns

Price Volatility

About the Company

Oramed Pharmaceuticals Inc. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources